Brief: Cyclacel Pharmaceuticals Reports New Clinical Data From Ongoing, Phase 2 Study Of Oral Fadraciclib At The 2024 Eortc-Nci-Aacr Symposium

Bio Green Med Solution

23/10/2024 16:02

Oct 23 (Reuters) - Cyclacel Pharmaceuticals Inc
 CYCC.O :
    * CYCLACEL PHARMACEUTICALS REPORTS NEW CLINICAL DATA FROM
ONGOING,
PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 EORTC-NCI-AACR
SYMPOSIUM
    * CYCLACEL PHARMACEUTICALS - INTERIM PHASE 2 DATA,
FADRACICLIB
WELL TOLERATED IN COHORT 8 WITH COMMON ADVERSE EVENTS

Source text for Eikon:  ID:nGNX5jNhTH 
Further company coverage:  CYCC.O 

 ((Reuters.Briefs@thomsonreuters.com))